Show simple item record

dc.contributor.authorSellahewa, Luckni
dc.date.accessioned2016-09-22T09:50:31Z
dc.date.available2016-09-22T09:50:31Z
dc.date.issued2014-01
dc.identifier.citationOpen Respir Med J. 2014 Jan 31;8:85-92. doi: 10.2174/1874306401408010085. eCollection 2014.language
dc.identifier.urihttp://hdl.handle.net/20.500.12904/565
dc.description.abstractInhaled corticosteroids (ICS) are the cornerstones in the management of bronchial asthma and some cases of chronic obstructive pulmonary disease. Although ICS are claimed to have low side effect profiles, at high doses they can cause systemic adverse effects including bone diseases such as osteopenia, osteoporosis and osteonecrosis. Corticosteroids have detrimental effects on function and survival of osteoblasts and osteocytes, and with the prolongation of osteoclast survival, induce metabolic bone disease. Glucocorticoid-induced osteoporosis (GIO) can be associated with major complications such as vertebral and neck of femur fractures. The American College of Rheumatology (ACR) published criteria in 2010 for the management of GIO. ACR recommends bisphosphonates along with calcium and vitamin D supplements as the first-line agents for GIO management. ACR recommendations can be applied to manage patients on ICS with a high risk of developing metabolic bone disease. This review outlines the mechanisms and management of ICS-induced bone disease.language
dc.language.isoenlanguage
dc.subjectBisphosphonatelanguage
dc.subjectBone Mineral Densitylanguage
dc.subjectOsteoporosislanguage
dc.subjectInhaled Corticosteroidslanguage
dc.titleInhaled corticosteroids and bone health.language
dc.typeArticlelanguage
refterms.dateFOA2021-06-03T10:09:07Z


Files in this item

Thumbnail
Name:
(192) Open Respir Med.pdf
Size:
1.681Mb
Format:
PDF

This item appears in the following Collection(s)

Show simple item record